Docstoc

SPI Transaction Curr

Document Sample
SPI Transaction Curr Powered By Docstoc
					    Case studies for technology trading
    and marketing cooperation in Japan
           Mineo Mori, Assistant General Manager
           Summit Pharmaceuticals International Corporation
•
•
•
•
•
•
   Food and Beverages                            €133,000,000
                                             Japan Region License
                                                for resminostat
   Pharmaceuticals
                                                    April 2011
MISSION            4SC discovers and develops targeted small-molecule therapies
                   against inflammation & cancer towards approval and/or
                   commercialization
FINANCE& SHARES      Founded in 1997
                     Market cap. ≈ €93 m (24 May 2012)
                     Prime Standard listing (@ Deutsche Börse) since 2005
History            2004 SPI starts agency work in Japan
                   2005 Sanwa Kagaku Research Collaboration, 1st deal in Japan
                   2009 4SC/SPI start introduction of resminostat in Japan
                   2011 Yakult License Agreement for Japan for resminostat
ATTRACTIVE GOALS     Vidofludimus: Phase IIb study in IBD in preparation
AHEAD                Resminostat: Pivotal program in preparation
                                                                YAKULT SALES OF
                                                               PHARMACEUTICALS
                  Major in-licensing activities                 (Billions of yen, Fiscal year)
2001   Debio      Oxaliplatin                             45
                                                          40
2005              Oxaliplatin launch in Japan
                                                          35
2007   Agennix    Satraplatin (Phase 3)                   30
                                                          25
2008   Celsion    ThermoDox (NDA, US)
                                                          20
2009   KHK        Neu-up G-CSF (Marketed, JP)             15
2011   Proacta    PR509 (Preclinical)                     10
                                                           5
2011   Aeterna    Perifosine (Phase 3, US/EU)              0
       Zentaris
2011   4SC        Resminostat (Phase 2, EU)
                  Oral HDAC inhibitor
                  potential to be used for solid tumors
                             To be presented on site
                                     CONFIDENTIAL
    •
    •
    •
    •
    •
                                     CONFIDENTIAL
    SPI supported 4SC on licensing
                                                       €133,000,000
    arrangement with Yakult
[Key turning points]
• Introduction to Yakult
                                                    Japan Region License
• Leading TS initiation to full                        for resminostat
  agreement discussion
• Spot-on advices on full agreement
• Maintain reliable communication at
  critical events                                        April 2011
• Convince both parties towards
  partnering
MISSION   Evotec offers services and alliances based on its state-of-the-art
          technology platform and a broad range of integrated capabilities spanning
          the drug discovery process.
History   • Founded in 1993, Evotec BioSystems AG goes public in 1999
          • SPI start its agency work in 2002
          • The agency work is focused on Contract Services
            Projects to date: 41 projects in Japan
            Major components of service:
          Screening Services, Assay development, Chemistry Project (LB synthesis),
          Medicinal Chemistry Services, Library Management, KINAXO services
          2002-2004 Screening services (hERG assay)
          2005-2007 Screening, Chemistry Project
          2008-     Size of deal Screening(especially FBDD approach to Med
                    Chem, EuroMs for several years), expansion to Proteomics
 1.     Key factors to success    compared with the other agencies or direct
        marketing)
       • Accumulation of steady works identifies Japanese customer’s needs
       • Budgeting of each project is generated by researchers and take formal
       steps to be authorized internally.
       • SPI is trying to collect information about each company’s research strategy.
       Marketing of wide-range clients enable us to contact various researchers.
       • Actually succeeded in agency work in Pharmaceutical research field
       • SPI has more than 30 years history with many track-records.
       • Long-term collaboration is possible
 2.     Difficult part of contract service business in Japan
          Takes long time to get budgeting in Japanese companies. Long-term
       persistent work is necessary to get a deal in Japanese companies.
  Metabolite analysis                                          GPCR profile
                                                               services
                                                                    Early stage product
      Antibody                                                      licensing
      Humanization
                                                                  Fragment Based
Contract Manufacturing                                            Drug Discovery
Arrangement of
biopharmaceuticals
                                 Regular base meeting with
                                 research planning dept.
              SPI can access to many range of information
              through our usual communication with Company X
    $272,000,000
 Asian Region License
 Asian Region License
     for RTA- 402
     for RTA- 402
    January 2010
    January 2010
                                   Currently 2,000 patient Phase 3 study
Nephrology   ESA (Erythropoietic Stimulating   ESPO®, NESP®
products     Agent) preparation
             Agent for secondary               REGPARA®,
             hyperparathyroidism               Rocaltrol®
   MISSION              Reata is the leader in developing a novel class of oral anti-
                        inflammatory drugs, Antioxidant Inflammation Modulators
                        (AIMs), which are potent activators of the biological
                        transcription factor Nrf2.
   FINANCE                Founded in 2002
                          Private company in Texas, USA
   History              2007 Found RTA-402 (bardoxolone) ‘s potency to CKD
                        2008 SPI starts agency work in Japan
                        2010 KHK License Agreement for Japan and Asian countries
   Projects               Bardoxolone: US/EU Phase III study in CKD on-going
                                       JAPAN Phase IIa study in CKD on-going
                          Follow up compounds : Phase I in preparation
2006            Reata initiated a Phase 1 trial of RTA 402 in solid tumors
2007            Found RTA-402 (bardoxolone) ‘s potency to CKD
2008            Two phase 2a studies with RTA402 initiated in CKD
       Autumn SPI starts agency work in Japan
2009   Spring   Announce Positive PIIa result at ADA
2010   Jan      Reata Licenses Bardoxolone to KHK in Asian territory
                Abbott and Reata Announce Agreement to Develop and Commercialize
       Sep
                Bardoxolone for CKD Outside the U.S.
2011   June     Reata and Abbott Initiate Global Phase 3 Study
                Abbott and Reata Announce Agreement to Develop and Commercialize
       Dec
                Next-Generation AIMs
                                  CONFIDENTIAL
•
•
•
•
•
                           CONFIDENTIAL
      $272,000,000
      $272,000,000
                                 •       Support to Reata Pharmaceuticals
                                         on licensing arrangement with
                                         Kyowa Hakko Kirin
                                 •       Support supply chain management
    Asian Region License
    Asian Region License                 for key API’s required for
        for RTA- 402
        for RTA- 402                     manufacturing of RTA-402
                                     [Key turning points]
                                     •    Preparative work before TS
       January 2010                  •    Spot-on advices on full agreement
                                     •    Advice on time keeping
TARGET   SCREENING   HITS Æ LEADS   Pc   PI   PII   P III   NDA   LAUNCH
•
•
•
•
•
•
    •
    •
    •
    •
    •
    •
•       Bio Japan World Business Forum
•       BIO Asia International Conference
•       BIO tech
•       Soffinova Biopharma Partnering Conference
http://www.takedaventures.com/   http://www.astellasventure.com/
http://www.mp-healthcare.com/
             •
             •
             •
             •
                                                                       Debt
                         Partnering       Marketing   API/manufact                 Direct
       Origin                                                          Loan
                          Support          Support    uring support             Investment
                                                                      service
SPI/Sumitomo                 SPI                          SPI         Oxford    Sumitomo
Corporation              Pharmaceutical     SPI
                                                       SC group       Finance     Corp.
“SOGO SHOSHA”             License dept.
  Investment Bank
  Financial Advisors                                                             (Support)
Partnering Consultants
 Trading Companies
                                                             26
•
•
•
•
•
•
                                   Agenda
 1. SC Corporate Profile
 2. MS Group Business overview
Sumitomo Corporation Head Office
                          Corporate Profile
                                   Sumitomo Corporation is one of the leading firms in the
                                   Japanese business arena, with its business continuously
                                   expanding into a diverse range of products and services.
                                   Since its foundation in the early 17th century, the
                                   “Sumitomo” Brand has represented stability and trust.
                                   The company’s reputation has been built upon the
                                   strong foundation of its long business tradition.
                                   Date of Establishment         December 24, 1919
                                   Number of Offices             116 overseas (65 countries), 24 in Japan
                                   Consolidated Subsidiaries     560 (421 overseas, 139 in Japan)
                                   Associated Companies          230 (176 overseas, 54 in Japan)
                                   Total Trading Transaction :   US$ 101 billion
                                   Gross Profit :                US$ 11.2 billion
                                   Net Profit :                  US$ 3.2 billion
       SC Head Office              Total Assets :                US$ 88 billion
                                   Shareholders’ Equity:         US$ 20.6 billion
                                   Number of Employees :         5,100 (72,030 including consolidated subsidiaries)
                                                                 * ¥82=U.S.$1 (as of March 2012)
                                                 Global Network
                                          CIS
       EUROPE
       headed by Sumitomo Corporation Europe Holding Limited
                                                                                                         NORTH
                   Sumitomo Deutschland GMBH                                                             AMERICA
MIDDLE EAST &
AFRICA
                                                  ASIA & OCEANIA
                                                                                     JAPAN
  Overseas:                    64 countries           Japan:                                                  CENTRAL AMERICA
                Subsidiaries 40 / 88 locations                     Headquarter             1 / 1 location     AND SOUTH AMERICA
                Branch        1 / 1 location                       Subsidiaries             3 / 9 locations
                Offices      25 / 25 locations                     Regional Business Units 3 / 12 locations
                Total          114 locations                       Offices                2 / 2 locations
                                                                   Total                    24 locations
        Sumitomo Corporation Europe Holding Limited/
               Sumitomo Deutschland GMBH
  Sumitomo Corporation Europe Holding Limited
    History       : Nov 1955       Set up Liaison office in London
                    Apr 1985       Establish Sumitomo Corp. UK
                    Jan 1999       change to Sumitomo Corp. Europe Holding
    Headquarter : London
    Employees     : 319
    Founding cap. : Euro 254,124,000
  Sumitomo Deutschland GMBH
    History                    : Jan 1952                 Set up Liaison office in Hamburg
                                 Nov 1952                 Move to Dusseldorf from Hamburg
                                 Apr 1958                 Establish Sumitomo Deutschland
                                 Sep 2001                 Spin off Pharmaceutical business to
                                                          Summit Pharmaceuticals Europe
    Headquarter : Dusseldorf
    Employees     : 54
    Founding cap. : Euro 30,610,964
                             Business Activities in Germany
                            by Sumitomo Deutschland GMBH
Trade                                   Investments                               Offices in Germany
                                                                                      Sumitomo Deutschland GmbH                   Sumitomo
Exports      ¾ Machinery &                                                                                                        Deutschland GmbH
             Equipment                  ¾International transportation                 Georg-Glock strasse 8 Dusseldorf, Germany
from
                                        (NVOCC)                                       Tel:+49- 211-45-700
Germany      ¾Organic Chemicals
                                          service
                                         (Sumisho Global Logistics                    Sumisho Global Logistics Europe GmbH
Imports      ¾Automotive                Europe                                        Georg-Glock strasse 8 Dusseldorf, Germany
             Components                                                               Tel:+49-211-45-70-290
to                                        GmbH)
Germany      ¾Agrochemicals
             ¾Organic & Function                                                       Sumi Agro Europe Ltd
               Chemicals                                                              Zweigniederlassung Deutschland (German Branch)
             ¾Non-ferrous Products                                                                                        Sumisho Global    Sumi Agro
                                                                                      Georg-Glock strasse 8 Dusseldorf, Germany
             ¾Machinery &                                                                                                 Logistics         Europe Ltd,
                                                                                      Tel:+49-211-45-70-206
             Equipment                                                                                                    Europe GmbH       German Branch
                                                                                                 Sumisho Global Logistics Europe GmbH
  Touch Panel                              Solar panel
  Automotive Parts for Navigation and      Polysilicon in its raw state (right) and              International transportation (NVOCC) service
  Entertainment modules.                   as a sliced wafer. Solar panels are                   Start from 1991
                                           made by laying processed wafer cells
                                           side-by-side.
                                     Business Unit in SC
                                                                                      Mineral Resources,                       New Industry
          Metal Products                      Infrastructure                          Energy, Chemical &                       Development
                                                                                          Electronics                         & Cross-function
                                                                                                                           Medical Science Dep.
       Transportation &                    Media, Network &                           General Products &
     Construction Systems                   Lifestyle Retail                             Real Estate
                 Organization of Life Science Business Unit
                                                     Mineral Resources, Energy,
                                                      Chemical & Electronics
                                                           Business Unit
 San Cristobal       Mineral            Mineral                                                                Basic           Electronics
                                                             Life Science                    Energy
   Project         Resources          Resources                                                              Chemicals          Business
                                                                                             Division
   Division       Division No.1      Division No.2             Division                                       Division          Division
  Agri-Science Dept                                   Medical Science Dept                              Pet Care Science Dept
        Brazilian Pesticide Company,                       Pharmaceutical Ingredient                           Pet Care Products Manufacturer,
        joitnly invested with Japanese                     Trading & License Business,                         one of the leading Pet Care
        Agriscience                                        Global bases                                        Company in US.
        Agrichemicals Distribution                        Minority Investment to Chinese                       Ceva Animal Health LLC / US ,
        Companies, with Global                            Pharmaceutical Company                               JV to Sales to Animal Health to
        Networks in EU, Asia, LA.                                                                              Veterinarians.
                                                           US Debt Financing company into
        Agrichemicals Distribution
                                                           new Technology at new Bio-
        division headquarter at Tokyo.
                                                           Technologies
                                                           Cosmetic Ingredient Formulation
                                                           & Distribution Company in the
                                                           US
                            Summit Pharmaceuticals Europe
Establishment : Jan 1997
              as spin off of Sumitomo Corporation Europe
Headquarter : Vintners’place - London
Branches      : Milano – Madrid
Main Activity : UK, Italy, Spain, Germany,
                Switzerland, Belgium, etc.
Employees     : 18
Founding cap. : GBP 1.614.000
Total turnover : Euro 34 mil.
                  SPE Organization
                  Corporate Management Dept (Milano)
                  Commercial Dept No.1 (London)
    C.E.O
                                        New Dev. (biology, licensing, etc)
                  Commercial Dept No. 2 (Milano)
                                        Cosmetic Biz
                  Commercial Dept No.3 (Madrid)
                       Agenda
1. SC Corporate Profile
2. MS Group Business overview
                                         Overview
   • Strong network in Key area of Pharmaceutical business
              with more than 200 experienced staffs strategically located
   • Accumulate experience to coordinate Pharmaceutical business
              with more than 40 years track record throughout every medical life
   • High reliability based on the basis of Sumitomo business spirit
              with more than US$ 300 million of trading transactions in the world
              Strong global network of SC and MS group
                                                                                Summit Pharmaceuticals China
                                  Summit Pharmaceuticals Europe
                                                                                           Sumitomo Corporation of Korea
Sumitomo Corporation of America
                                    London           Milanan
                                                     Milana                                    g
                                                                                         Beijing
                                                       Mila
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M
                                                       Mi
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M
                                                       M la
                                                       Mila
                                                       Milan
                                     Madrid
                                     Madrid                                             Nanjing
                                                                                        Nanjing                    Tokyo
                                                                                                                   Tokyo
               New York
                                                                                         Shanghai                  Osaka
                                                                                                                   Osaka
                                                                                                 Seoul
                                                                                                 Seoul
                                                                                                 Seoul
                                                                                                 Seou
                                                                      Mumbai
                                                                      Mumbai                           Sumitomo Corporation
                                                                                                       Medical Science Group
                                                                               Ch
                                                                               Chennai
                                                                                     i
                                                                               Chennai                 Summit Pharmaceuticals
                                                                                                       International
                                                          Sumitomo Corporation India
                                       SC      Overseas Offices and Subsidiaries
                                                                                                                   SC
                                                                 Sumitomo Corpor
                                                                 Sumito
                                                                    itomo Corporation Subsidiaries
                                                                             porati
                                    MS Group Overseas Offices and Subsidiariesation Subsidiaries and Offices
                                                                                         sidiar         ffices
                                                                                                             s
                                                                                                       Offi es
                                                               z Sumitomo Corporation Subsidiaries and Offices
                                                                      MS Group Overse Offices nd Subsidiaries
                                                                             p
                                                                      MS Gro p Ove as Office and Subsidiaries
                                                                    z MS Group Overseas Offices and Subsidiaries
                                                                    z MS Group Overseas Offices and Subsidiaries
                 More than 200 experienced staffs are strategically located
                to add our precious values to both customers and suppliers.
    Many experiences: multi-functional services
TARGET       SCREENING      HITS Æ LEADS    Pc      PI    PII    P III   NDA     LAUNCH
                                                                  Production, Marketing
                                                  Supply of FDF, APIs, Intermediates
                                              Direct Investment
                                 Providing Debt
          Licensing of New Drugs and Diagnostics
  Research Collaboration
     Chemical Library
         MS Group turnover is over US$ 300s mil / y of multi transactions
                      in the world pharmaceutical sector.
                                  Case Study
a) API Supply Chain Coordination
b) Research Collaboration, with Metabolon Inc.
c) Pharmaceutical company in China, C&O Pharmaceutical
                                   Case Study 1
                       - Supply Chain Coordination
Local presence, accumulated experience and integrated information enable us
• to select cost-competitive and reliable supplier
• to monitor supplier’s performance and progress
• to ensure on-time supply
                            Raw Material                                    API, FDF
       EU
                        CHINA
                        KOREA JAPAN                                          US
                  INDIA
                                                                 SC
        Intermediate
                 API
                                   Case Study 1
                       - Supply Chain Coordination
                                                 Sumitomo global network
                                                             Advanced               Raw
     Customer              Sumitomo     API                Intermediate            Material
    SPE can provide seamless supply chain with advantages of
    - Save unnecessary cost of each trader, vendor
    - Ensure on time delivery by controlling all suppliers at once
    - Monitor each supplier’s performance and progress at once
                                        Trader                            Trader
                                        Vendor                            Vendor
                             CMO
                                                        Advanced                        Raw
      Customer                                        Intermediate                     Material
                             API
                                                Case Study 2
                                           - with Metabolon Inc.
               Science and technology-driven company
                  providing solutions through global
                        biochemical profiling
Mebabolon Overview                                    Clients;
• Founded in 2000                                     • 1400+ studies
• Over 125+ employees worldwide                       • Pharmaceuticals, Biotechs, Govt.
                                                          agencies, Academic groups
• New 37,000 sq. ft. facility in RTP, NC
• Over 1,400 completed projects                       Application;
• Over 55 peer-reviewed publications                  • Disease Mechanism, Diagnostics,
                                                        Bioprocessing, Cell Culture,
• 19 issued patents                                     Biomarkers, Vaccines, Agriculture,
• Advanced metabolomic technology                       Nutrition, Toxicity, Drug safety,
                                                        Compound Profiling
                                                Case Study 2
                                           - with Metabolon Inc.
                                                    DNA                Biochemistry
                                                                       Advantages
                                                    RNA
                                                                     Any sample type
                                                  Proteins           Many applications
OH                           OH        O                                Fewer total
     O    OH
                                           OH
HO        OH
     OH                           NH
                                       2         Metabolism            biochemicals
glucose        cholesterol   L-threonine
                                                  Disease            Solutions through
                                                 Mechanism
                                                                      Understanding
                                                                        Metabolism
                                                           Case Study 2
                                          - with Metabolon Inc.
                                 Complex
      Biological
                                 Metabolite                             Analysis of Biochemistry   Solution
      Question
                                   Data
                            Benign
 Prostate Cancer                                                                                   Sarcosine modulates
 Aggressiveness                                                                                        invasiveness
                           Localized
                                               Metabolon
                                                                   800
                                                                 0 800
                                                               400-800
                                               Software                als/
                                                                       als/
                                                              biochemicals/
                                                                      e
                                                                 sample
                                                                              Z-score
                          Metastatic
                            Ø
                   Hundreds of thousands ion
                        features/study
                                                           Case Study 3
                                         - C&O Pharmaceutical
History                : Funded in 1999,
                         listed in Singapore Exchange in Oct. 2005,
                         SC joined in Dec.’10., Shionogi joined in Oct.’11.
Turnover               : HK$650mil. (US$83mil. , FY09)
Employee               : 1,300 (sales900, R&D100, admi.100, prod.200)
Products               : 28 C&O branded products, 7 imported products
Development            : 25projects of category1(new drug in the world) & category3(new
                       drug launched in other markets, not in China) are under develop,
                         Focus on Anti-Infective, Adult Disease, Digestive, and Anti-Tumor.
Specialties            : - Exclusive distributor of
                           ¾ Meiji Seika’s Cefditoren pivoxil “Meiact”
                           ¾ Shionogi’s Latamoxef “Furumarin”
                         - Extensive network covering over 300,000 hospitals, clinics
                           and pharmacies with 900 sales persons
                         - Joint Venture CRO service – XBL China
                             Case Study 3
                      - C&O Pharmaceutical
SPE support to maximize business possibility from Europe to China with
• licensing out the market the compounds developed by European partners
• helping development work as CRO
• supplying competitive/reliable API
                         Licensing
      EU
                      CHINA/
                       C&O
             API                                   SC
     We hope to support your business
    by utilizing our competitive functions
     from the point of view of diversity.
      Thanks for paying your attention.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:0
posted:4/22/2013
language:English
pages:25